Advances in molecular therapies for targeting pathophysiology in spinal cord injury. (4th March 2023)

• Record Type: Journal Article
• Authors: Kim, Ha Neui; McCrea, Madeline R.; Li, Shuxin
• Is Part Of: Expert opinion on therapeutic targets. Volume 27:Number 3(2023)
• Page Start: 171
• Page End: 187
• Publication Date: 2023-03-04
• Subjects: Spinal cord injury -- treatment -- neuroprotection -- cell death -- neuronal regeneration -- neural repair -- functional recovery; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2023.2194532
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Spinal cord injury (SCI) affects 25, 000–50, 000 people around the world each year and there is no cure for SCI patients currently. The primary injury damages spinal cord tissues and secondary injury mechanisms, including ischemia, apoptosis, inflammation, and astrogliosis, further exacerbate the lesions to the spinal cord. Recently, researchers have designed various therapeutic approaches for SCI by targeting its major cellular or molecular pathophysiology. Areas covered: Some strategies have shown promise in repairing injured spinal cord for functional recoveries, such as administering neuroprotective reagents, targeting specific genes to promote robust axon regeneration of disconnected spinal fiber tracts, targeting epigenetic factors to enhance cell survival and neural repair, and facilitating neuronal relay pathways and neuroplasticity for restoration of function after SCI. This review focuses on the major advances in preclinical molecular therapies for SCI reported in recent years. Expert opinion: Recent progress in developing novel and effective repairing strategies for SCI is encouraging, but many challenges remain for future design of effective treatments, including developing highly effective neuroprotectants for early interventions, stimulating robust neuronal regeneration with functional synaptic reconnections among disconnected neurons, maximizing the recovery of lost neural functions with combination strategies, and translating the most promising therapies into human use.